Cerevel Therapeutics Holdings, Inc. (CERE) |
41.9 -0.09 (-0.21%) 04-24 16:00 |
Open: | 41.94 |
High: | 42.06 |
Low: | 41.87 |
Volume: | 618,818 |
Market Cap: | 7,608(M) |
PE Ratio: | -15.69 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 49.76 |
Resistance 1: | 42.60 |
Pivot price: | 41.97 |
Support 1: | 41.73 |
Support 2: | 41.19 |
52w High: | 43.59 |
52w Low: | 19.59 |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
EPS | -2.670 |
Book Value | 3.710 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -24.7 |
Return on Equity (ttm) | -72.4 |
Sat, 20 Apr 2024
Calamos Advisors LLC Takes Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) - MarketBeat
Thu, 18 Apr 2024
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Stud - Benzinga
Fri, 12 Apr 2024
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Short Interest Up 38.2% in March - MarketBeat
Wed, 03 Apr 2024
Cerevel Therapeutics director sells $2.12m in stock, buys $175k worth - Investing.com
Wed, 03 Apr 2024
Director N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE) - Yahoo Finance
Wed, 06 Mar 2024
Cerevel Therapeutics: Parkinson's Could Be The Issue (NASDAQ:CERE) - Seeking Alpha
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |